Skip to main content
SpringerLink
Log in
Book cover

Immuntherapie in der Uroonkologie pp 46–55Cite as

Immuntherapie des metastasierten Nierenzellkarzinoms mit rekombinantem Interferon-γ

  • Conference paper

  • 22 Accesses

Zusammenfassung

Das Nierenzellkarzinom (NZK) ist ein Tumor, der gegen Chemotherapie resistent ist. Die berichtete durchschnittliche Überlebensrate bei Patienten mit metastatischer Krankheit beträgt ungefähr 10 Monate (Maldazys u. de Kernion 1986). Vor kurzem wurden jedoch experimentelle und klinische Beweise dafür erbracht, daß das NZK gegenüber verschiedenen Formen der Immuntherapie, einschließlich der IL-2-Behandlung mit oder ohne adopti-vem Transfer von lymphokinaktivierten Killerzellen (LAK-Zellen) oder Interferon (IFN)-γ verhältnismäßig sensibel ist (Graham 1989). In diesem Bericht präsentieren wir vorklinische Daten und revidieren unsere jüngsten Erfahrungen mit der Entwicklung einer effektiven Immuntherapie für Patienten mit fortgeschrittenem NZK unter Verwendung von IFN-y.

Übersetzung aus dem Engl, von Belinde Junkers.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aulitzky W, Gastl G, Aulitzky WE et al. (1987) Interferon-gamma for the treatment of metastatic renal cancer: Dose-dependent stimulation and down-regulation of soluble beta-2 microglobulin and neopterin responses. Immunobiology 176: 85–89

    Article  PubMed  CAS  Google Scholar 

  • Aulitzky W, Gastl G, Aulitzky WE et al. (1989) Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 7: 1875–1884

    PubMed  CAS  Google Scholar 

  • Aulitzky WE, Aulitzky W, Frick J et al. (1990) Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factoralpha. Immunobiology 180: 385–394

    Article  PubMed  CAS  Google Scholar 

  • Aulitzky WE, Grosse-Wilde H, Westhoff U et al. (1991) Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). Clin Exp Immunol 86: 236–239

    Article  PubMed  CAS  Google Scholar 

  • Bander NH (1989) Monoclonal antibodies to renal cancer antigens. Semin Urol 7: 264–270

    PubMed  CAS  Google Scholar 

  • Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cancer: isolation, characterization and anti-tumor activity. Cancer Res 48: 206–210

    PubMed  CAS  Google Scholar 

  • Boon T (1992) Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 58: 177–210

    Article  PubMed  CAS  Google Scholar 

  • Cordon-Cardo C, Fuks Z, Drobnjak Z, Moreno C, Eisenbach L, Feldman M (1991)

    Google Scholar 

  • Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51: 6372–6380

    Google Scholar 

  • de Riese W, Allhoff E, Kirchner H, Stief CG, Atzpodien J, Maschek H, Jonas U (1991) Complete spontaneous regression in metastatic renal cell carcinoma — an update and review. World J Urol 9: 184–191

    Google Scholar 

  • Elliot BE, Carlow DA, Rodricks A, Wade A (1989) Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 53: 181–245

    Article  Google Scholar 

  • Garnick MB, Reich SD, Maxwell (1988) Phase I/II study of recombinant interferon-gamma in advanced renal cell carcinoma. J Urol 139: 251–255

    PubMed  CAS  Google Scholar 

  • Gastl G, Huber C (1988) The biology of interferon actions. Blut 56: 193–199

    Article  PubMed  CAS  Google Scholar 

  • Gastl G, Marth C, Leiter E et al. (1985) Effects of recombinant alpha-2 arg-interferon and gamma-interferon on human breast cancer cell lines: Dissociation of antiproliferative activity and induction of HLA-DR expression. Cancer Res 45: 2957–2961

    PubMed  CAS  Google Scholar 

  • Graham SD (1989) Immunotherapy of renal cell carcinoma. Semin Urol 7: 215–227

    PubMed  Google Scholar 

  • Grups JW, Frohmueller HGW (1989) Cyclic interferon-gamma treatment of patients with metastatic renal carcinoma. Br J Urol 64: 218–220

    Article  PubMed  CAS  Google Scholar 

  • Heicappel R, Ackermann R (1991) Current strategies for immunotherapy of renal cell carcinoma. World J Urol 9: 204–209

    Article  Google Scholar 

  • Levin I, Kuperman O, Goldstein J et al. (1991) Cellular β-2 microglobulin expression as a prognostic indicator in renal cell carcinoma. Acta Oncol 30: 941–945

    Article  PubMed  CAS  Google Scholar 

  • Maldazys JD, de Kernion JB (1986) Prognostic factors in metastatic renal cell carcinoma. J Urol 136: 376–379

    PubMed  CAS  Google Scholar 

  • Maluish AE, Urba WJ, Longo DL et al. (1988) The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6: 434–441

    PubMed  CAS  Google Scholar 

  • Osband ME, Ross S (1990) Problems in the investigational study and clinical use of cancer immunotherapy. Immunol Today 11: 24–31

    Article  Google Scholar 

  • Otto U, Schneider A, Denkhaus H, Conrad S (1988) Die Behandlung des metastasierenden Nierenkarzinoms mit rekombinantem alpha-2- oder gamma-interferon. Onkologie 11: 185–191

    Article  PubMed  CAS  Google Scholar 

  • Quesada JR, Kurzrock R, Sherwin SA (1987) Phase II studies of recombinant interferon- gamma in metastatic renal cell carcinoma. J Biol Respir Mod 6: 20–27

    CAS  Google Scholar 

  • Rinehart JJ, Malspeis I, Young D (1986) Phase I/II trial of human recombinant interferon gamma in advanced renal cell carcinoma. J Biol Respir Mod 5: 300–308

    CAS  Google Scholar 

  • Takaku H, Kumamoto Y, Koiso K et al. (1987) Phase II study of recombinant human interferon-gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Cancer 60: 929–933

    Article  Google Scholar 

  • Trinchieri G, Perussia B (1985) Immune interferon: A pleiotropic lymphokine with multiple effects. Immunol Today 6: 131–136

    Article  CAS  Google Scholar 

  • Weiner LM, Steplewski Z, Koprowski H, Litwin S, Comis RL (1988) Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Res 48: 1042–1049

    PubMed  CAS  Google Scholar 

  • Zinkernagel RM, Döherty PC (1979) MHC cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T cell restriction: Specificity, function and responsiveness. Adv Immunol 27: 51–78

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Gastl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. H. Bander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Frick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Aulitzky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Universitätsklinikum Essen, Hufelandstr. 55, W-4300, Essen 1, Deutschland

    Herbert Rübben  & Mark Goepel  & 

  2. Urologische Universitätsklinik, Moorenstr. 5, W-4000, Düsseldorf 1, Deutschland

    Bernd J. Schmitz-Dräger

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Gastl, G., Bander, N.H., Frick, J., Huber, C., Aulitzky, W. (1993). Immuntherapie des metastasierten Nierenzellkarzinoms mit rekombinantem Interferon-γ. In: Rübben, H., Goepel, M., Schmitz-Dräger, B.J. (eds) Immuntherapie in der Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77830-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77830-8_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77831-5

  • Online ISBN: 978-3-642-77830-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation